An active androgen receptor (AR) is required in CRPC. Post-translational modification plays an important role in AR activation and, ultimately, in the subset of genes targeted for transcription.

The first RIPTAC has just hit the clinic. Learn about this new technology that is being developed by Halda Therapeutics.

Within target cells, testosterone is converted to 5α-dihydrotestosterone (DHT), a more potent androgen, by 5α-reductase. Both testosterone and DHT bind to the AR to exert their physiological ...

Abstract Highlights ORIC-944 is a potent, highly selective, orally bioavailable, allosteric inhibitor of PRC2 that demonstrates best-in-class drug properties, including potency, solubility, and ...

PARP7 is a mono-ADP-ribosyl transferase (mono-ART) which has recently gained attention due to its emerging role as a negative ...

Haisco Pharmaceutical Group Co. Ltd. has identified proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase binding moiety covalently linked to an androgen receptor (AR) ...

ON ASTRAZENECA ASSAY DEVELOPMENT PROJECTS AND SUCCESSFUL COMPLETION OF EISAI CONTRACT Development of both the prostate cancer ...

Qingdao Putaike Biomedical Technology Co. Ltd. has described androgen receptor full length (AR-FL) and/or androgen receptor variant 7 (AR-v7) degradation inducers reported to be useful for the ...

Cassiopea has filled that gap with a first-in-class acne treatment, Winlevi, a topical androgen receptor (AR) inhibitor. Although the exact mechanism of action is unknown, in vitro studies show ...